Pfizer, BioNTech Launch COVID-19 Vaccine Trial In Kids Under
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said. The first volunteers in the early-stage trial were given their first injections on March 24, Pfizer spokesperson Sharon Castillo said.

The Pfizer/BioNTech vaccine was authorized by U.S. regulators in late December for people age 16 and older. Nearly 66 million doses of the vaccine had been administered in the United States as of March 24 morning, according to data from the U.S. Centers for Disease Control and Prevention.

The pediatric trial, which will include children as young as 6 months, follows a similar one launched by Moderna Inc last week. Only the Pfizer/BioNTech vaccine is being used in 16- and 17-year-olds in the United States. Moderna’s shot was cleared for those age 18 and older, and no COVID-19 vaccine has been authorized in younger kids yet.

Pfizer and BioNTech plan to initially test the safety of their two-shot vaccine at three different dosages - 10, 20, and 30 micrograms - in a 144-participant Phase I/II trial. They plan to later expand to a 4,500-participant late-stage trial in which they will test the safety, tolerability, and immune response generated by the vaccine, likely by measuring antibody levels in the young subjects.

Source:
https://www.reuters.com/article/us-health-coronavirus-pfizer-children-idUSKBN2BH2LM
Like
Comment
Share